Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 3:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 714 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Insulin Resistance Syndrome Clear all
Completed Phase 1Phase 2 Interventional Results available

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions
Rosiglitazone, Recombinant human growth hormone + rosiglitazone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic and Bio-behavioral Effects of Following Recommendations in the Dietary Guidelines for Americans

NCT04293224
View directory record Official record
Conditions
Obesity, Body Weight
Interventions
DGA Mediterranean diet pattern, energy balance, DGA Mediterranean diet pattern, negative energy balance, TAD diet pattern, negative energy balance
Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
19 Years to 64 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Not applicable Interventional Results available

Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine

NCT00512070
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity, Metabolic Syndrome
Interventions
olanzapine and melatonin
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 11, 2026, 3:08 PM EDT
Recruiting Phase 2 Interventional

Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

NCT05054296
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Educational Intervention, Exercise Intervention, FitBit, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Device · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 11, 2026, 3:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant

NCT00920842
View directory record Official record
Conditions
Cardiovascular Complications, Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
9 Years to 21 Years
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

NCT00417170
View directory record Official record
Conditions
High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
Interventions
Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Dietary Flavonoids on Intestinal Microbiota, Intestinal Inflammation and Metabolic Syndrome

NCT02728570
View directory record Official record
Conditions
Metabolic Syndrome X, Inflammation
Interventions
High Dietary Flavonoids, Low Dietary Flavonoids
Other
Lead sponsor
Utah State University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03248882
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Placebo, PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
60
States / cities
Bakersfield, California • Chula Vista, California • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Not applicable Interventional

Implementing Digital Health in a Learning Health System

NCT03713333
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension, Heart Failure, Atrial Fibrillation, Metabolic Syndrome, Genetic Disease
Interventions
Digital Health Device Diagnostics
Diagnostic Test
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes

NCT02023918
View directory record Official record
Conditions
Diabetes, Metabolic Syndrome, Insulin Resistance
Interventions
pegvisomant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Paleolithic Diets vs T2D and Improvements in the Metabolic Syndrome

NCT00548782
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Paleolithic diet, ADA ( American Diabetes Association) recommended diet
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 11, 2026, 3:08 PM EDT
Recruiting Not applicable Interventional

Food and Fitness With Medicine (FFWM)

NCT07027995
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome, Type 2 Diabetes
Interventions
Exercise is Medicine (EIM), Culinary Education, Food is Medicine, Nutrition Counseling, Participant Website
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Columbus, Ohio • Upper Arlington, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Phase 4 Interventional Results available

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.

NCT00988364
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Simvastatin, Vytorin, Placebo, Ezetimibe
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome

NCT01411293
View directory record Official record
Conditions
Cardiovascular Disease, Metabolic Syndrome, Obesity
Interventions
Low-Fat Milk, Rice Milk
Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Not applicable Interventional Results available

Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or Older

NCT04421014
View directory record Official record
Conditions
Metabolic Syndrome, Normal Cognition
Interventions
Ketone Ester drink, Placebo: isocaloric dextrose drink
Dietary Supplement
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 11, 2026, 3:08 PM EDT
Active, not recruiting No phase listed Observational

Anti-obesity Pharmacotherapy and Inflammation

NCT05756764
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
35 Years to 60 Years
Enrollment
30 participants
Timeline
2023 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 11, 2026, 3:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dedicated Breast CT for Quantitative Breast Density Measurements in Mexican-origin Women in Southern Arizona

NCT04799665
View directory record Official record
Conditions
Metabolic Syndrome, Obesity Associated Disorder
Interventions
Breast CT
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Not applicable Interventional

Can Neural Network Instability in Schizophrenia be Improved With a Very Low Carbohydrate Ketogenic Diet?

NCT05268809
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Ketogenic diet
Other
Lead sponsor
Northern California Institute of Research and Education
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Not applicable Interventional Results available

Intermittent Fasting Adherence and Self Tracking

NCT04836312
View directory record Official record
Conditions
Hypertension, Obesity
Interventions
Soft Commitment Device
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Phase 1 Interventional

MANP in Hypertension and Metabolic Syndrome

NCT03781739
View directory record Official record
Conditions
Hypertension, Metabolic Syndrome
Interventions
MANP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Phase 2 Interventional Results available

Metformin in Kidney Disease

NCT02252081
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease, Metabolic Syndrome
Interventions
metformin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

NCT00400231
View directory record Official record
Conditions
Metabolic Syndrome x
Interventions
Study drugs: Metformin and fenofibrate, Study Drug: Metformin, Study Drug: fenofibrate, Metformin and Fenofibrate placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 11, 2026, 3:08 PM EDT
Completed Not applicable Interventional

Light and the Effect on Metabolic Syndrome and Alzheimer's Disease

NCT03777722
View directory record Official record
Conditions
Alzheimer Disease, Diabetes Mellitus, Type 2
Interventions
Tailored Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
New Brunswick, New Jersey • Albany, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 11, 2026, 3:08 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome

NCT07218653
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Indomethacin, Placebo, MRI
Drug · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 11, 2026, 3:08 PM EDT